Skip to site services
Skip to top navigation
Skip to main content
Skip to footer
Alert service | Downloads | Glossary | Print this page Print this page | Site map
Vectura is developing inhaled pharmaceuticals and has two key franchises: respiratory and neurology
Vectura is a leader in the development of inhaled pharmaceuticals, using ideas, technologies and skills to create products to treat respiratory, neurological and other diseases – rapidly and effectively. Our goal is to improve patients’ lives and generate value for our stakeholders.

Share price

42.75 GBp  +0.50 VEC.L
Market cap GB£ 133
Date 04/07/2008
 Share price information

Next events

24-25 June 2008
Piper Jaffray Conference, London 25-26 June 2008
Jefferies Healthcare Conference, New York  Investor Calendar
Delivered by Investis logo and link to website (opens in a new window)